Pharmacotherapies targeting inflammatory pathways and neurotransmitters improve cognitive scores in patients with Alzheimer's diseaseNew analysis shows specific drug targets may help Alzheimer's patients

This network meta-analysis synthesized data from 68,398 patients with Alzheimer's disease to evaluate various pharmacological strategies. The analysis included interventions targeting inflammatory pathways, neurotransmitters, the gut-brain axis, amyloid-beta (Aβ), and synaptic plasticity/neuroprotection compared against a placebo control group.

The primary outcome measure was the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). Results indicated that interventions targeting inflammatory pathways were superior to placebo with an effect size of SMD = -0.24 (95% CI: -0.40 to -0.08). Similarly, interventions targeting neurotransmitters demonstrated superiority over placebo with an effect size of SMD = -0.22 (95% CI: -0.29 to -0.15). A sensitivity analysis for interventions targeting the gut-brain axis also showed superiority over placebo with an effect size of SMD = -0.26 (95% CI: -0.51 to -0.01).

Secondary outcomes included the Clinical Dementia Rating-Sum of Boxes and the Mini-Mental State Examination. For the Clinical Dementia Rating-Sum of Boxes, no significant differences were observed between intervention groups and placebo. However, interventions targeting neurotransmitters significantly improved scores on the Mini-Mental State Examination compared to placebo, with a mean difference (MD) of 0.61 (95% CI: 0.37 to 0.86).

Safety data revealed distinct profiles across different intervention classes. Interventions targeting neurotransmitters, amyloid-beta (Aβ), and synaptic plasticity/neuroprotection were associated with an increased risk of adverse events compared with placebo. Furthermore, interventions specifically targeting Aβ and synaptic plasticity/neuroprotection also raised the risks of serious adverse events. Notably, the risk of death did not differ significantly across any groups.

These findings contribute to the evolving landscape of Alzheimer's disease management by identifying specific pathways that may offer cognitive benefits. While several strategies were evaluated, the study noted a limited evidence base for certain strategies within the analysis. The results suggest that while inflammatory and neurotransmitter-focused therapies show promise in improving ADAS-Cog scores, they must be weighed against their respective safety profiles.

Clinically, these results imply that pharmacotherapies targeting neurotransmitters, the gut-brain axis, and inflammatory pathways may offer comparatively favorable cognitive benefits in Alzheimer's disease. However, because different classes—specifically those targeting Aβ and synaptic plasticity—carry higher risks of serious adverse events, a careful benefit-risk assessment is required for individual patients.

Several questions remain regarding the long-term durability of these effects and the specific mechanisms by which gut-brain axis interventions produce improvements. Additionally, more robust data are needed to clarify the safety profile of inflammatory pathway medications compared to other classes. The limited evidence base for certain strategies highlights a need for further primary research in those specific areas.